MBX Biosciences is a clinical-stage biopharmaceutical company developing novel precision peptide therapies for people living with endocrine and metabolic disorders. Its proprietary Precision Endocrine Peptide (PEP) platform engineers long-acting peptide prodrugs, and its pipeline includes canvuparatide (MBX 2109) for chronic hypoparathyroidism… - View it on GitHub